Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00106418
Status:
COMPLETED
Last Update Posted:
2019-11-18
First Post:
2005-03-24
Brief Title:
A Research Study for Patients With Prostate Cancer
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
An Exploratory Phase II Multicenter Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the activity of romidepsin depsipeptideFK228 in patients with metastatic prostate cancer who have developed a rising prostate specific antigen PSA while undergoing hormonal therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None